Learn how to administer the AIMS with tips, interactive severity assessment, and extra practice videos.
Learn more about tardive dyskinesia, VMAT2 Inhibitors, and related practice models and tools. Attend live to have your questions answered by the experts.
Mark your calendar and get registered early for these live webinars.
Learn to administer the Abnormal Involuntary Movement Scale (AIMS) assessment with these three interactive ACPE-accredited sessions.
Antipsychotic medications are a central part of the treatment process for those with schizophrenia and other mental health conditions, including depression and bipolar disorder. As a result, the potential for an antipsychotic to contribute to the development of a drug induced movement disorder continues to be a clinical concern. Adverse events such as drug induced movement disorders play an important role in treatment considerations when quality of life and medication adherence must be considered. One part of offering quality care is being able to assess the effectiveness and tolerability of medication using movement disorder assessment tools to help identify both the presence and severity of movements. Drug induced movement disorder assessment tools are not diagnostic and should not substitute for other differential assessments; however, they can serve as a tool to more effectively use medications. In these microsessions, you will receive instruction on how the Abnormal Involuntary Movement Scale (AIMS) can be utilized in practice to better assess patients for tardive dyskinesia and learn more about tardive dyskinesia.
This activity has been supported through an independent educational grant from Neurocrine Biosciences Inc. and Teva Pharmaceuticals.